Contemporary Clinical Trials Communications
Elsevier Inc.
United States
journal
SJR by Edition
Subject Categories
- Medicine (miscellaneous)Q2
- PharmacologyQ2
Areas: Medicine · Pharmacology, Toxicology and Pharmaceutics
Most published research topics
Source: OpenAlex
Publication Statistics
Documents per Year
Detailed Information
ISSN
2451-8654
SJR Best Quartile
Q2
Region
Northern America
Citations per Document (2 years)
1.62
References per Document
40.48
Coverage
2015-2026
Scope
This companion title to Contemporary Clinical Trials is an international peer reviewed open access journal that publishes articles pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted to Contemporary Clinical Trials Communications should appeal to a readership drawn from a wide range of disciplines including medicine, life science, pharmaceutical science, biostatistics, epidemiology, computer science, management science, behavioral science, and bioethics. Contemporary Clinical Trials Communications is unique in that it is outside the confines of disease specifications, and it strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings irrespective of their perceived importance, significance or impact. Both randomized and non-randomized trials are within the scope of the Journal. Some common topics include trial design rationale and methods, operational methodologies and challenges, and positive and negative trial results. In addition to original research, the Journal also welcomes other types of communications including, but are not limited to, methodology reviews, perspectives and discussions. Through timely dissemination of advances in clinical trials, the goal of Contemporary Clinical Trials Communications is to serve as a platform to enhance the communication and collaboration within the global clinical trials community that ultimately advances this field of research for the benefit of patients.
Metrics from SCImago Journal Rank 2025. View on SCImago